Related stories
Making Science Announces Webinar on Third-Quarter Results
Making Science announced a webinar to present its third-quarter results.
M impact | EQUITY | Oct 29, 2026, 05:32 PM UTC
OSE Immunotherapeutics Reports Phase 2 Tedopi Combo Survival Data
In metastatic NSCLC, one-year overall survival was 47% with Tedopi plus docetaxel and 46% with Tedopi plus nivolumab, versus 29% with docetaxel. Median overall survival was 11.9 an
M impact | EQUITY | Oct 29, 2026, 05:32 PM UTC
KBR Reports Third-Quarter 2026 Revenue of $2.03 Billion, EPS of $1.06
Revenue rose 5% year over year to $2.03 billion, net income increased 16.2% to $136 million, and diluted EPS climbed 17.8% to $1.06. Sustainable Technology Solutions growth offset
M impact | EQUITY | Oct 29, 2026, 05:32 PM UTC
Canada to Take Up to CA$1.6 Billion Equity Stake in Cohere
The Canadian government is taking an equity stake of up to CA$1.6 billion in Toronto-based Cohere.
M impact | EQUITY | Oct 29, 2026, 05:32 PM UTC
OSE Immunotherapeutics Says Tedopi Combinations Meet Phase 2 Trial Primary Endpoint
OSE Immunotherapeutics said Tedopi combinations met the primary endpoint in a Phase 2 lung cancer trial.
M impact | EQUITY | Oct 29, 2026, 05:30 PM UTC
Glaukos shares soar 31% amid heavy trading
Glaukos shares rose 31% amid heavy trading.
M impact | EQUITY | Oct 29, 2026, 05:30 PM UTC